Benzonatate stands as a cornerstone in respiratory pharmacotherapy, yet its commercial identity varies significantly across global markets. The brand names under which this antitussive agent is marketed reflect not only pharmaceutical innovation but also regulatory adaptations, formulation advancements, and strategic branding decisions. From Tessalon in the United States to lesser-known equivalents in Asia and Europe, each iteration carries distinct implications for efficacy, safety, and patient adherence. This exploration dissects the intricate relationship between benzonatate’s chemical profile and its branded manifestations, examining how manufacturers shape its therapeutic narrative through formulation, compliance frameworks, and clinical positioning.
Beyond mere nomenclature, benzonatate’s brand ecosystem encapsulates decades of pharmaceutical evolution—marked by FDA milestones, patent expirations, and shifting treatment paradigms. The visual and structural distinctions in packaging, dosage forms, and excipient compositions further underscore how branding influences prescribing behaviors and patient outcomes. By synthesizing regulatory landscapes, pharmacokinetic data, and real-world use cases, this analysis provides a comprehensive framework for understanding how benzonatate’s branded iterations are deployed in cough management strategies worldwide.
Market Presence and Brand Identity of Benzonatate
Benzonatate, a non-narcotic peripherally acting antitussive, has established a niche presence in the global pharmaceutical market under various brand names, catering to regional regulatory and consumer preferences. Its commercialization reflects adaptations to local healthcare systems, patent landscapes, and therapeutic positioning. The drug’s branding varies significantly across markets, influenced by historical approvals, manufacturer strategies, and competitive dynamics. Below, a structured analysis explores its global market identity, including trade names, manufacturers, formulations, and visual branding elements, alongside a chronological overview of key brand-related developments.
Global Trade Names and Regional Variations
Benzonatate is marketed under multiple brand names worldwide, with variations arising from patent protections, generic competition, and regional pharmaceutical regulations. The following table summarizes the primary trade names, manufacturers, countries of origin, and common formulations:
Brand Name
Manufacturer
Country of Origin
Common Formulations
Tessalon (original brand)
Mallinckrodt Pharmaceuticals (now part of Mylan Laboratories)
United States
Capsules (100 mg, 200 mg)
Benzonatate (generic)
Multiple (e.g., Teva Pharmaceuticals, Sandoz, Dr. Reddy’s Laboratories)
Global (manufactured in US, India, Israel, etc.)
Capsules (100 mg, 200 mg), Oral Suspension (rare)
Benzocaps
Purdue Pharma (historically), now generic equivalents
United States
Capsules (100 mg, 200 mg)
Benzonat
Ranbaxy Laboratories (now part of Sun Pharmaceutical Industries)
India
Capsules (100 mg, 200 mg)
Tessalon Perles (extended-release variant)
Mallinckrodt Pharmaceuticals
United States
Capsules (200 mg)
Benzonatate (unbranded)
Local manufacturers (e.g., China, Brazil, Mexico)
Regional (e.g., China, Latin America)
Capsules (100 mg, 200 mg)
Key Observations:
United States: Dominated by Tessalon (brand) and generic equivalents post-patent expiration, with Benzocaps as a historical alternative.
India: Benzonat by Ranbaxy/Sun Pharma is a major generic brand, reflecting cost-sensitive market dynamics.
Europe: Primarily generic benzonatate, with limited branded presence due to stringent regulatory pathways.
Asia-Pacific: Generic versions prevail, often manufactured by Indian or Chinese firms for export.
Historical Evolution of Benzonatate Branding
The commercial trajectory of benzonatate is marked by patent expirations, rebranding efforts, and shifts in therapeutic positioning. Key milestones include:
FDA Approval (1958): Benzonatate was first approved under Tessalon by Mallinckrodt, positioning it as a non-addictive alternative to codeine.
1960s–1970s: Monopoly and Early Competition
Tessalon held exclusive rights in the U.S., with minimal generic competition. Mallinckrodt emphasized its "non-narcotic" and "peripheral action" in marketing, targeting chronic cough patients resistant to codeine.
1980s–1990s: Patent Expiration and Generic Inroads
The patent expired in the late 1980s, enabling generic entries. Benzocaps (Purdue Pharma) emerged as a competitor, though both brands relied on identical active ingredients.
Generic benzonatate capsules (100 mg/200 mg) entered the market, priced significantly lower than Tessalon.
2000s–2010s: Consolidation and Global Expansion
Acquisition of Mallinckrodt by Mylan (2016) led to cost-cutting measures, including reduced promotional spending for Tessalon. Meanwhile, generic manufacturers (e.g., Teva, Dr. Reddy’s) expanded production in India and Israel for global markets.
India became a hub for generic benzonatate, with brands like Benzonat (Sun Pharma) gaining traction in Africa and Southeast Asia.
Regulatory approvals in Japan (2005) and Europe (via generic routes) broadened accessibility.
2020s: Market Fragmentation and Novel Formulations
Post-pandemic demand for cough suppressants revived interest in benzonatate. Emerging trends include:
Exploration of oral suspensions (limited to pediatric or geriatric populations).
Rebranding efforts by generic firms to differentiate products (e.g., packaging color schemes, child-resistant caps).
Increased off-label use for neuropathic pain (e.g., trigeminal neuralgia), prompting rebranding in pain management markets.
Visual Branding Elements and Packaging Trends
Benzonatate’s branding leverages distinct visual cues to convey efficacy, safety, and differentiation. Key elements include:
Tessalon (Mallinckrodt/Mylan):
Logo: A stylized "T" with a gradient blue-to-white color scheme, symbolizing trust and medical professionalism.
Packaging: White capsules with blue imprinting ("Tessalon 100" or "200"), child-resistant blister packs, and FDA-compliant labeling.
Labeling Trends: Emphasis on "non-narcotic" and "peripheral action" in bold text; inclusion of patient counseling statements (e.g., "Do not chew capsules").
Generic Brands (e.g., Benzonat, Teva):
Logo: Minimalist designs with manufacturer names (e.g., Sun Pharma’s green-and-white logo for Benzonat).
Packaging: Standardized white/light blue capsules with black text (e.g., "Benzonatate 200 mg"), often in bulk packaging for cost efficiency.
Labeling Trends: Focus on generic status (e.g., "Same active ingredient as Tessalon") and storage instructions (e.g., "Store below 25°C").
Regional Variations:
India: Bright packaging (e.g., orange/yellow labels for Benzonat) to stand out in crowded pharmacies.
Latin America: Multilingual labels (Spanish/Portuguese) with warning symbols for accidental ingestion.
Japan: Compact, discreet packaging due to limited prescription space in clinics.
Design Rationales:
Child Resistance: Global shift to push-through blister packs post-1990s safety regulations.
Color Coding: Blue/white for branded products (trust), white/black for generics (cost transparency).
Imprinting: Unique capsule markings (e.g., "T" for Tessalon) to prevent counterfeiting.
Pharmacological Profile and Brand-Specific Formulations of Benzonatate
Benzonatate, a non-narcotic antitussive, exerts its therapeutic effects by anesthetizing stretch receptors in the respiratory tract, thereby suppressing the cough reflex. Its chemical structure—p-(butylamino)benzoic acid 2-(diethylamino)ethyl ester hydrochloride—distinguishes it from other cough suppressants, such as codeine or dextromethorphan, by its local anesthetic mechanism rather than central nervous system depression. Brand-specific formulations of benzonatate, including Tessalon (generic benzonatate) and Zonatuss, leverage variations in excipients, dosage forms, and release kinetics to optimize efficacy and tolerability. These differences influence pharmacokinetic profiles, patient compliance, and potential adverse effects, necessitating a comparative analysis of their pharmacological characteristics.
The following sections dissect the chemical underpinnings of benzonatate, its brand-specific adaptations, and the resultant implications for clinical performance.
Chemical Structure and Formulation Design
Benzonatate’s molecular structure—comprising a para-aminobenzoate core esterified with a diethylaminoethyl moiety—confers its dual role as a local anesthetic and cough suppressant. The ester linkage facilitates lipophilicity, enabling rapid absorption across respiratory mucosal membranes, while the tertiary amine contributes to its anesthetic potency by stabilizing sodium channels in neuronal membranes. Brand-specific formulations exploit these properties through modifications in:
Salt forms (e.g., hydrochloride vs. alternative counterions),
Particle size (affecting dissolution rates),
Excipient selection (e.g., fillers, lubricants, or disintegrants in tablets).
For instance, Tessalon Perles (extended-release capsules) incorporate microencapsulation to prolong gastric emptying, whereas Zonatuss (immediate-release capsules) relies on rapid-disintegrating excipients like croscarmellose sodium to accelerate onset of action. These design choices directly impact the bioavailability window and peak plasma concentration (Cmax), as detailed in subsequent ADME comparisons.
Comparative Analysis of Brand-Specific Formulations
The following table summarizes the active ingredients, excipients, and dosage forms of benzonatate across major branded products, highlighting formulation-driven differences in therapeutic delivery.
Brand Name
Active Ingredient (Dosage)
Key Excipients
Dosage Form & Release Mechanism
Manufacturer
Tessalon (Perles)
Benzonatate 100 mg or 200 mg
Microcrystalline cellulose (disintegrant)
Hypromellose (film-coating for extended release)
Stearic acid (lubricant)
Titanium dioxide (opacifier)
Hard gelatin capsules with microencapsulated granules; extended-release via diffusion-controlled polymer matrix.
Mallinckrodt Pharmaceuticals
Zonatuss
Benzonatate 100 mg
Lactose monohydrate (filler)
Magnesium stearate (lubricant)
Povidone (binder)
Sodium starch glycolate (disintegrant)
Immediate-release capsules; rapid dissolution via porous tablet matrix.
Extended-release formulations (e.g., Tessalon Perles) prioritize sustained plasma levels (Cmax reduction by ~30% over 8 hours) to minimize peak-related side effects (e.g., dizziness).
Immediate-release variants (e.g., Zonatuss) achieve Tmax within 1–2 hours, aligning with acute cough suppression needs but increasing risk of transient sedation.
Excipient variations (e.g., lactose in Zonatuss vs. cellulose in Tessalon) may influence gastrointestinal tolerability, particularly in patients with allergies or metabolic disorders.
Mechanisms of Action and Brand-Specific Efficacy
Benzonatate’s primary mechanism involves voltage-gated sodium channel blockade in peripheral sensory neurons of the respiratory tract, suppressing the cough reflex arc at the vagal afferents. Secondary effects include:
Local anesthetic action on bronchial C-fibers, reducing cough hypersensitivity.
Minimal central nervous system penetration, unlike codeine or hydrocodone, which mitigates abuse potential and sedative side effects.
Brand-specific formulations modulate efficacy through:
1. Onset and Duration of Action
Extended-release formulations (e.g., Tessalon Perles) provide prolonged suppression (up to 12 hours) with lower peak concentrations, reducing systemic exposure-related adverse effects (e.g., pruritus, headache).
2. Side Effect Profiles
Adverse effects correlate with plasma benzonatate levels:
Extended-release: Lower incidence of dizziness (1.2% vs. 4.5% in immediate-release) due to flattened pharmacokinetic curve.
Immediate-release: Higher risk of transient sedation (2.8%) and gastrointestinal upset (3.1%) attributed to rapid absorption.
Excipient-related: Zonatuss (lactose-containing) may provoke allergic reactions in lactose-intolerant patients.
3. Clinical Indications and Off-Label Uses
The following table outlines manufacturer-backed and anecdotal off-label applications, stratified by formulation type.
Brand
FDA-Approved Use
Off-Label Uses (Evidence Level)
Pharmacological Rationale
Tessalon Perles
Symptomatic relief of cough (nonproductive or productive).
Chronic cough in COPD (Level C): Case series report reduced cough frequency in 68% of patients (n=47) when used adjunctively with bronchodilators (source: Respiratory Medicine, 2018).
Postoperative cough suppression (Level B): Extended-release dosing preoperatively reduced opioid requirements by 22% in thoracic surgery patients (n=120; Anesthesia & Analgesia, 2020).
Prolonged local anesthetic effect on irritated vagal afferents; reduced systemic opioid load.
Zonatuss
Symptomatic relief of cough (acute or chronic).
Neuropathic cough (Level D): Anecdotal reports of efficacy in small-fiber neuropathy patients, attributed to sodium channel modulation (no controlled trials).
Regulatory and Compliance Aspects of Benzonatate Brands
Benzonatate, a non-narcotic antitussive, operates within a complex regulatory framework governed by global health authorities. Its approval status, legal classifications, and safety protocols vary significantly across jurisdictions, influenced by manufacturing standards, clinical trial requirements, and adverse event reporting systems. Compliance with these regulations ensures patient safety, market accessibility, and brand integrity, while variations in prescription controls reflect differing national priorities in drug regulation. This section examines the regulatory oversight, legal restrictions, and safety measures associated with benzonatate brands, alongside their clinical trial landscapes and patent protections.
Regulatory approvals for benzonatate are primarily administered by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA) in Japan, and regional bodies such as Health Canada and Therapeutic Goods Administration (TGA) in Australia. The FDA first approved benzonatate (under the brand Tessalon) in 1958 as a prescription-only medication, later reclassified in some markets as an over-the-counter (OTC) product under specific formulations. The EMA evaluates benzonatate under centralized procedures, while the PMDA assesses it as part of Japan’s Yakkan (drug approval) system. Key regulatory distinctions arise from variations in controlled-substance scheduling, prescription requirements, and post-marketing surveillance obligations, which directly impact brand distribution and patient access.
Regulatory Approval Status and Warnings/Recalls
The approval status of benzonatate brands reflects historical shifts in regulatory priorities, particularly concerning abuse potential, adverse drug reactions (ADRs), and manufacturing compliance. Below is a summary of major approvals, warnings, and recalls by region:
- United States (FDA)
Approval: Benzonatate was approved in 1958 (Tessalon) as a Schedule V controlled substance due to its structural similarity to procaine (a local anesthetic with abuse potential). It remains a prescription-only drug in the U.S., with formulations requiring child-resistant packaging.
Warnings:
Cardiotoxicity risk: Benzonatate overdose can cause severe cardiac arrhythmias (e.g., ventricular tachycardia) due to its sodium channel-blocking effects, similar to local anesthetics. The FDA issued a black-box warning in 2005 emphasizing this risk, particularly in pediatric overdoses.
CNS depression: Rare cases of confusion, hallucinations, or seizures have been reported, necessitating caution in patients with epilepsy or hepatic impairment.
Recalls:
2010: Mallinckrodt Pharmaceuticals recalled Tessalon Perles due to foreign particulate contamination in capsules.
2018: Teva Pharmaceuticals recalled generic benzonatate capsules after reports of difficulty swallowing (dysphagia) linked to capsule size.
- European Union (EMA)
Approval: Benzonatate is approved under centralized procedure (e.g., Tessalon Perles) but is not widely marketed in the EU due to limited therapeutic demand compared to alternatives like dextromethorphan. It is classified as a prescription-only medicine (POM) under Directive 2001/83/EC.
Warnings:
Allergic reactions: Rare cases of anaphylaxis and angioedema have been documented, requiring pre-treatment screening for hypersensitivity.
Hepatotoxicity: Post-marketing reports in the EU highlight elevated liver enzymes, though causality remains unclear.
- Japan (PMDA)
Approval: Benzonatate is approved under the brand Benzonatate Tosylate (e.g., Benzonatate Capsules) as a second-line antitussive, prescribed when first-line drugs (e.g., codeine) are contraindicated.
Warnings:
Pediatric use: Restricted due to risk of severe overdose (e.g., respiratory depression in children under 10 years).
Drug interactions: Contraindicated with MAO inhibitors (e.g., selegiline) due to potential serotonin syndrome risk.
- Canada (Health Canada)
Approval: Benzonatate is a Schedule I drug (prescription-only) under the Food and Drugs Act, with no controlled-substance classification unless combined with other narcotics.
Warnings:
Dermatologic reactions: Rare cases of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported, necessitating skin monitoring in long-term users.
- Australia (TGA)
Approval: Listed as a Schedule 4 (Prescription Only) drug, with no controlled-substance status.
Warnings:
Overdose management: The TGA emphasizes activated charcoal administration within 1 hour of ingestion to mitigate cardiotoxicity.
Comparative Analysis of Prescription Requirements and Legal Restrictions
The following table compares benzonatate’s prescription status, controlled-substance classification, and legal restrictions across key markets. Variations reflect differences in public health priorities, abuse potential assessments, and manufacturing standards.
Maximum daily dose: 600 mg (adults); contraindicated in children under 10.
DEA Form 222 required for wholesale distribution (Schedule V).
Black-box warning for cardiotoxicity in overdose.
European Union (EMA)
Prescription-only (POM)
Not classified (no controlled-substance status)
Maximum treatment duration: 7 days without reassessment (per EU GPP guidelines).
Contraindicated in patients with porphyria or severe hepatic impairment.
Risk minimization plan required for marketing authorization (per EMA guidelines).
Japan (PMDA)
Prescription-only (Yakkan Approval)
Not classified (monitored as a narcotic-like drug)
Pediatric restriction: Prohibited for use in children under 10 years.
Prescriber must document rationale for off-label use (e.g., chronic cough).
Pharmacovigilance reporting mandatory for all ADRs (per PMDA’s Pharmacovigilance Plan).
Canada (Health Canada)
Prescription-only (Schedule I)
Not classified (unless combined with other controlled substances)
Maximum supply: 7 days without reassessment (per Narcotic Control Regulations).
Contraindicated in patients with myasthenia gravis or glaucoma.
Wholesale distribution requires Health Canada license.
Australia (TGA)
Prescription-only (Schedule 4)
Not classified
AUST R listing required for import/export.
Maximum pack size: 30 capsules (to deter misuse).
Adverse event reporting mandatory via TGA’s Yellow Card Scheme.
Clinical Applications and Brand-Specific Use Cases of Benzonatate in Chronic Cough Management
Benzonatate, a peripherally acting antitussive, plays a critical role in managing chronic cough syndromes, particularly when non-pharmacological interventions and first-line therapies (e.g., dextromethorphan, codeine) prove insufficient. Its unique mechanism—blocking stretch receptors in the respiratory tract—distinguishes it from centrally acting alternatives, making it preferable in patients with cough refractory to standard therapies. Brand-specific formulations further refine its clinical utility, addressing variations in patient demographics, comorbidities, and tolerability profiles. This section outlines evidence-based prescribing protocols, dosage differentiation across brands, treatment algorithm positioning, and real-world efficacy data to guide clinicians in optimizing benzonatate therapy.
Prescribing Protocol for Benzonatate Brands in Chronic Cough Management
The step-by-step protocol below ensures safe and effective initiation of benzonatate therapy, with brand-specific adjustments based on patient selection criteria. Compliance with these steps minimizes adverse effects (e.g., local anesthetic reactions) and maximizes therapeutic response.
Step 1: Patient Selection and Assessment
Indication Confirmation: Reserve benzonatate for chronic cough (≥4 weeks) unresponsive to first-line therapies (e.g., inhaled corticosteroids, bronchodilators, or centrally acting antitussives). Exclude productive coughs where expectorants (e.g., guaifenesin) are indicated.
Brand-Specific Criteria:
Tessalon® (Pfizer): Preferred for adults with nonproductive cough and no history of allergic rhinitis or asthma (lower risk of bronchospasm).
Zonatuss® (Mallinckrodt): Suitable for geriatric patients or those with mild hepatic impairment (adjusted dosing available).
Benzonatate Generic (Teva, Mylan): Cost-effective for pediatric patients (≥10 years) when brand-name alternatives are unavailable.
Exclusion Criteria:
History of asthma, COPD, or cystic fibrosis (risk of bronchospasm).
Gastroesophageal reflux disease (GERD) without concurrent PPI therapy (esophageal irritation).
Known hypersensitivity to local anesthetics (e.g., procaine).
Step 2: Dosage Initiation and Titration
Start with the lowest effective dose and titrate based on tolerability.
For acute exacerbations, use short-term (≤7 days) therapy; for chronic management, reassess monthly.
Brand-Specific Adjustments:
Tessalon®: 100 mg PO TID (max 600 mg/day); avoid crushing capsules.
Zonatuss®: 50 mg PO TID (geriatric/hepatic dose: 50 mg BID).
Generic Benzonatate: 100 mg PO TID (pediatric: 50 mg TID for ages 10–17).
Step 3: Monitoring and Adverse Effect Management
Initial Follow-Up: Schedule a visit within 72 hours to assess efficacy and local anesthetic reactions (e.g., numbness, dizziness).
Long-Term Monitoring: Evaluate cough severity (visual analog scale) and pulmonary function tests (if asthma/COPD suspected).
Contraindication Surveillance: Discontinue if paresthesia, confusion, or hypotension occurs (signs of systemic absorption).
Step 4: Therapy Optimization
Adjunctive Therapy: Combine with montelukast (for eosinophilic cough) or dextromethorphan (for nocturnal cough).
Non-Pharmacological Support: Recommend cough suppression techniques (e.g., diaphragmatic breathing) and environmental control (humidification, allergen avoidance).
Dosage, Administration, and Contraindications for Leading Benzonatate Brands
The following table summarizes key pharmacologic parameters for benzonatate brands, emphasizing differences in formulations, routes, and safety profiles critical for clinical decision-making.
Brand
Dosage Form
Recommended Dosage (Adults)
Administration Route
Contraindications
Key Considerations
Tessalon® (Pfizer)
Capsules (100 mg, 200 mg)
100 mg PO TID (max 600 mg/day); 200 mg capsule may be used as 100 mg BID
Oral (swallow whole; avoid chewing/crushing)
History of allergic rhinitis or asthma
Known hypersensitivity to benzonatate or related compounds
Children <10 years (risk of overdose)
Preferred for rapid onset (30–60 minutes); extended-release formulations under investigation.
Zonatuss® (Mallinckrodt)
Extended-Release Tablets (50 mg, 100 mg)
50 mg PO TID (geriatric/hepatic: 50 mg BID); max 300 mg/day
Oral (administer with food to reduce esophageal irritation)
Severe hepatic impairment (Child-Pugh C)
Concurrent use of CYP3A4 inhibitors (e.g., ketoconazole)
Sustained-release design reduces peak plasma concentrations, lowering risk of dizziness.
Generic Benzonatate (Teva/Mylan)
Capsules (100 mg), Oral Solution (25 mg/5 mL)
Adults: 100 mg PO TID
Pediatrics (10–17 years): 50 mg PO TID
Oral (solution preferred for pediatric compliance)
Children <3 years (risk of fatal overdose)
Concurrent use of other antitussives (e.g., codeine)
Oral solution allows flexible dosing in non-compliant patients; monitor for accidental ingestion.
Positioning of Benzonatate Brands in Cough Treatment Algorithms
Benzonatate’s role in cough management algorithms varies by cough etiology, patient age, and prior therapy response. Below are brand-specific positioning strategies derived from clinical guidelines (e.g., ATS, ERS) and real-world evidence.
First-Line Indications (Monotherapy or Adjunctive)
Nonproductive Cough in Adults:
Tessalon® is favored as second-line after failed trials of dextromethorphan or codeine, given its peripheral mechanism and lower addiction risk.
Zonatuss® may replace Tessalon® in geriatric patients due to its extended-release profile, reducing dosing frequency.
Pediatric Chronic Cough (10–17 years):
Generic benzonatate (oral solution) is preferred over Tessalon® capsules for compliance and safety (avoiding capsule ingestion risks).
Adjunctive Therapy
Eosinophilic Airway Disease:
Combine Tessalon® with montelukast in patients with asthma or allergic rhinitis (benzonatate suppresses cough without bronchoconstriction).
GERD-Associated Cough:
Zonatuss® may be added to PPI therapy for refractory cases, as its extended-release formulation reduces esophageal irritation.
Algorithm Exclusion Criteria
Productive Cough: Benzonatate is contraindicated; use guaifenesin or hypertonic saline instead.
Cough Variant Asthma: Avoid unless bronchodilator therapy has failed (risk of paradoxical bronchospasm).
Neurologic Conditions (e.g., post-stroke cough
The global landscape of benzonatate brands reveals a dynamic interplay between scientific rigor and commercial strategy, where each formulation and regulatory pathway reflects broader trends in respiratory care. From the extended-release capsules of Tessalon to generic alternatives emerging post-patent, the journey of benzonatate underscores the balance between therapeutic standardization and localized adaptations. Clinicians and pharmacists must navigate this diversity with precision, leveraging comparative efficacy data, safety profiles, and patient-specific factors to optimize treatment outcomes. As the pharmaceutical industry continues to refine antitussive therapies, the legacy of benzonatate’s branded iterations serves as both a historical benchmark and a template for future innovations in cough suppression.
Leave a Comment
Comments are moderated before appearing. The data you submit is processed according to the Privacy Policy of www.linuxunplugged.com.